Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.21 USD | +8.33% | +2.31% | -68.52% |
Financials (USD)
Sales 2024 * | 428K | Sales 2025 * | 300K | Capitalization | 6.85M |
---|---|---|---|---|---|
Net income 2024 * | -26M | Net income 2025 * | -33M | EV / Sales 2024 * | 16 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 22.8 x |
P/E ratio 2024 * |
-0.47
x | P/E ratio 2025 * |
-0.57
x | Employees | 19 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.2% |
Latest transcript on TFF Pharmaceuticals, Inc.
1 day | +8.33% | ||
1 week | +2.31% | ||
Current month | -19.05% | ||
1 month | -26.58% | ||
3 months | -62.55% | ||
6 months | -70.04% | ||
Current year | -68.52% |
Managers | Title | Age | Since |
---|---|---|---|
Harlan Weisman
CEO | Chief Executive Officer | 71 | 18-11-30 |
Kirk Coleman
DFI | Director of Finance/CFO | 51 | 18-01-23 |
Zamaneh Mikhak
CTO | Chief Tech/Sci/R&D Officer | 59 | 23-01-08 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 52 | 18-11-30 | |
Brandi Roberts
BRD | Director/Board Member | 50 | 22-03-24 |
Thomas King
BRD | Director/Board Member | 69 | Dec. 12 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-24 | 2.21 | +8.33% | 29,991 |
24-05-23 | 2.04 | -6.42% | 114,851 |
24-05-22 | 2.18 | -2.68% | 11,174 |
24-05-21 | 2.24 | -2.18% | 50,806 |
24-05-20 | 2.29 | +6.02% | 63,504 |
Delayed Quote Nasdaq, May 24, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-68.52% | 6.85M | |
+67.53% | 63.85B | |
-0.77% | 41.83B | |
+45.66% | 40.65B | |
-10.72% | 27.12B | |
+13.30% | 26.52B | |
-22.79% | 18.69B | |
+4.70% | 12.73B | |
+24.10% | 12.11B | |
+27.41% | 12.07B |
- Stock Market
- Equities
- TFFP Stock